Drawing parallels between amyloid PET in Alzheimer's disease and amino acid PET in primary and secondary brain tumors.

Nelleke Tolboom, Antoine Verger, Matthias Preusser, Marjolein Geurts, Philip Scheltens, Nathalie Lisa Albert

Abstract read

In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nelleke TolboomDepartment of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands (N.T.); Department of Nuclear Medicine and Nancyclotep Imaging Platform, IADI, INSERM U1254, Université de Lorraine, Nancy, France (A.V.); Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria (M.P.); Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, The Netherlands (M.G.); Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (M.G.); EQT Life Sciences Amsterdam Amsterdam, The Netherlands (P.S.); of Nuclear Medicine, LMU University Hospital, LMU LMU Munich, Munich, Germany (N.A.).ORCID https://orcid.org/0000-0002-8005-2833

Antoine Verger

Matthias PreusserORCID https://orcid.org/0000-0003-3541-2315

Marjolein GeurtsORCID https://orcid.org/0000-0003-2369-0035

Philip Scheltens

Nathalie Lisa AlbertORCID https://orcid.org/0000-0003-0953-7624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The evolution of amyloid PET in Alzheimer's disease illustrates the potential path of amino acid PET in neuro-oncology. Initially seen as of limited value, amyloid PET ultimately enhanced diagnostic accuracy, guided management, and became central once therapies demonstrated PET-measured efficacy. Amino acid PET for CNS tumors is at a similar turning point. It refines diagnosis, distinguishes progression from treatment effects, and supports treatment planning. As demand grows and tracer access improves, amino acid PET could follow amyloid PET's trajectory: emerging as a key tool in precision medicine and clinical management and as a surrogate endpoint in therapeutic trials.

Identifiers

PMID41798683

DOI10.1093/noajnl/vdag043

PMCPMC12962851

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.